Market Overview

Here's Why Carbylan Therapeutics Lost Nearly Half Of Its Value


Shares of Carbylan Therapeutics Inc (NASDAQ: CBYL), a nano-cap clinical-stage specialty pharmaceutical company, plunged nearly 50 percent after the company announced top-line results from a Phase 3 trial, COR1.1.

COR1.1 was a 560 patient, international, multi-center and randomized double-blind study that evaluated the safety and efficacy of Hydros-TA. The primary endpoints of the trial were changes from baseline in the WOMAC A pain scores at week 2 for Hydros-TA versus Hydros and at week 26 for Hydros-TA versus TA.

Carbylan Therapeutics reported that the study met the first of its two primary endpoints and demonstrated a statistically significant improvement from baseline in the WOMAC A pain score at week 2 versus Hydros. However, the company noted that patients in the TA arm continued to show an unexpected significant reduction in pain through 26 weeks. Given the comparable effectiveness at 26 weeks, COR1.1 did not meet its second primary endpoint.

"We are pleased to have achieved one of our primary endpoints in our COR1.1 trial. This demonstrates that Hydros-TA can provide early onset of pain relief with a low-dose corticosteroid," stated David Renzi, President and CEO of Carbylan Therapeutics, "However, patients who received the corticosteroid triamcinolone acetonide, or TA, showed a prolonged pain-reduction through 26 weeks, which was unexpected based on clinical experience and published literature. We are very pleased that Hydros-TA and Hydros performed as expected throughout the course of the study, and we are actively reviewing the trial data in order to better understand the reported duration of effect of TA at 26 weeks. We look forward to sharing with our investors our future plans for the continued development of Hydros-TA."

Posted-In: Carbylan Therapeutics Clinical Stage Companies COR1.1 David RenziNews Health Care Movers General


Related Articles (CBYL)

View Comments and Join the Discussion!

Amazon Is Taking Over Your Home

Oppenheimer Hits Fitbit With Outperform, Says Global Opportunity Just Beginning